eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology Horn, L., Wu, Y., Reck, M., Wakelee, H., Liang, C., Harrow, K., Oertel, V., Mok, T. 2018; 29 Suppl 8: viii543

View details for DOI 10.1093/annonc/mdy292.121

View details for PubMedID 32137417